Study of the Role of Interferon αon the Endothelial Dysfunction During Septic Shock
NCT ID: NCT04204694
Last Updated: 2021-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2020-07-01
2023-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Septic shock is defined by an acute circulatory failure, with low blood pressure and insufficient oxygen supply to organs. This circulatory failure is related to vascular damages, in which the endothelial vascular tissue is impaired by inflammatory mechanisms, with release of circulating endothelial cells in the blood.
Therefore, modulating inflammation on the vascular endothelial tissue could be a therapeutic strategy, and the investigators focus on the role of the type I interferons on the endothelial tissue because of the demonstrated role of type I interferons during septic shock.
Thus the investigators proceed to an observational study, in which the primary purpose will be to show a higher expression of type I interferon receptors on circulating endothelial cells in patients with septic shock compared to control subjects.
Concerning secondary purposes, the investigators will record mortality at d3, d7 and d28, perform assays about types I, II and III interferons in plasma, and test anti-interferon on endothelial cells ex vivo
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Septic Shock-induced Immunosuppression
NCT04067674
Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis
NCT05681442
Empiric Antibiotic Treatment for Septic Patients in the Intensive Care Unit
NCT05924126
Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock.
NCT04080453
Pediatric Immune Response to Infectious Shock
NCT02848144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient in septic shock
3-time blood sampling for septic shock patients
15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
blood donor tests
Only one blood sampling for controls patients
15 mL blood are sampled from a blood donation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3-time blood sampling for septic shock patients
15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
Only one blood sampling for controls patients
15 mL blood are sampled from a blood donation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Blood donors
Exclusion Criteria
* Age \< 18 years old
* Absence of written consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de réanimation médicale
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7350
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.